There were 49 press releases posted in the last 24 hours and 171,193 in the last 365 days.

Merck Announces First-Quarter 2017 Financial Results

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2017.

“Merck delivered solid performance across our broad range of products that address major disease categories and the needs of global health,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “The continued momentum of KEYTRUDA in oncology, along with the strength of the vaccine and other franchises and animal health, helped to drive revenue growth in the quarter.”

Financial Summary

         
$ in millions, except EPS amounts       First Quarter
2017       2016
Sales $9,434 $9,312
GAAP EPS 0.56 0.40

Non-GAAP EPS that excludes certain items1*

0.88 0.89

GAAP net income2

1,551 1,125
Non-GAAP net income that excludes certain items1,2*       2,437       2,492

*Refer to table on page 7.

 

Worldwide sales were $9.4 billion for the first quarter of 2017, an increase of 1 percent compared with the first quarter of 2016, including a 2 percent negative impact from foreign exchange.

GAAP (generally accepted accounting principles) earnings per share assuming dilution (EPS) were $0.56 for the first quarter of 2017. Non-GAAP EPS of $0.88 for the first quarter of 2017 excludes acquisition- and divestiture-related costs, restructuring costs and certain other items.

Pipeline Highlights

Merck continued to deliver significant progress in the development program for KEYTRUDA (pembrolizumab), an anti-PD-1 therapy, receiving key regulatory approvals or opinions and supplemental Biologics License Application (sBLA) acceptances.

  • The U.S. Food and Drug Administration (FDA) approved under its Accelerated Approval program KEYTRUDA for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or for patients with cHL who have relapsed after three or more prior lines of therapy.
  • The European Commission approved KEYTRUDA for the first-line treatment of non-small cell lung cancer (NSCLC) in adults whose tumors have high PD-L1 expression (tumor proportion score of 50 percent or more) with no EGFR or ALK positive tumor mutations.
  • The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of KEYTRUDA for the treatment of adult patients with relapsed or refractory cHL who have failed autologous stem cell transplant and brentuximab vedotin (BV), or who are transplant-ineligible and have failed BV.
  • The FDA accepted for review under its Accelerated Approval program the sBLA for KEYTRUDA in combination with pemetrexed and carboplatin for the treatment of patients with metastatic or advanced NSCLC regardless of PD-L1 expression. This is the first application for regulatory approval of KEYTRUDA in combination with another treatment. The FDA granted Priority Review with a PDUFA action date of May 10, 2017.
  • The FDA accepted and granted Priority Review for the sBLA for the treatment of patients with locally advanced or metastatic urothelial cancer, a type of bladder cancer, for first-line use in patients who are ineligible for cisplatin-containing therapy. The application for second-line use was also accepted for Priority Review. The PDUFA action date for both applications is June 14, 2017.
  • The company recently submitted additional data and analyses to the FDA for the pending sBLA application for the treatment of previously treated patients with advanced microsatellite instability-high cancer. The PDUFA action date for this Priority Review has been extended to June 9, 2017.

The FDA and EMA accepted for review three New Drug Applications (NDAs) in the company’s diabetes franchise for medicines containing ertugliflozin, an investigational SGLT2 inhibitor in development to help improve glycemic control in adults with type 2 diabetes as part of Merck’s collaboration with Pfizer Inc. The PDUFA action date from the FDA is in December 2017 for the three NDAs.

Merck presented phase 3 data across our late-stage pipeline in studies that met their primary endpoints.

  • At the Conference on Retroviruses and Opportunistic Infections in February, data were presented from the ongoing “DRIVE-FORWARD” phase 3 clinical trial evaluating the safety and efficacy of doravirine (MK-1439), an investigational non-nucleoside reverse transcriptase inhibitor for previously untreated adults with HIV-1 infection. The study met its primary efficacy endpoint, demonstrating the non-inferiority of once-daily doravirine to once-daily ritonavir-boosted darunavir.
  • Positive results from a study of letermovir, an investigational antiviral medicine for the prevention of cytomegalovirus infection in high-risk bone marrow transplant patients, were presented at the BMT Tandem Meetings in February.
  • Merck presented data from a trial for V212, an investigational inactivated varicella zoster virus vaccine for the prevention of herpes zoster or HZ, also known as shingles. The data demonstrated a reduction in the incidence of confirmed HZ cases by an estimated 64 percent in immunocompromised patients and also were presented at the BMT Tandem Meetings.

First-Quarter Revenue Performance

The following table reflects sales of the company’s top pharmaceutical products, as well as total sales of Animal Health products.

         
$ in millions       First Quarter
                  Change
2017 2016 Change Ex-Exchange
Total Sales $9,434 $9,312 1% 3%
Pharmaceutical 8,185 8,104 1% 2%
JANUVIA / JANUMET 1,335 1,412 -5% -5%
KEYTRUDA 584 249 134% 137%
ZETIA / VYTORIN 575 889 -35% -35%
GARDASIL / GARDASIL 9 532 378 41% 41%
ZEPATIER 378 50 * *

PROQUAD, M-M-R II and VARIVAX

355 357 0% 1%
ISENTRESS 305 340 -10% -10%
REMICADE 229 349 -34% -31%
ROTATEQ 224 188 19% 19%
Animal Health 939 829 13% 14%
Other Revenues       310       379       -18%       -5%

*Growth comparison not meaningful due to ongoing product launch.

Pharmaceutical Revenue

First-quarter pharmaceutical sales increased 1 percent to $8.2 billion, including a 1 percent negative impact from foreign exchange. The growth was driven by oncology, hepatitis C and vaccines, largely offset by the loss of market exclusivity for several products, as well as lower sales in the diabetes franchise.

Growth in oncology was due to higher sales of KEYTRUDA as the company continues to launch the product with new indications globally.

Growth in hepatitis C was driven by ZEPATIER (elbasvir and grazoprevir), a medicine for the treatment of chronic hepatitis C virus genotypes 1 or 4 infection, due to ongoing launches globally. Sales in the United States also reflect an approximately $40 million favorable adjustment to rebate accruals due to mix of business.

Growth in vaccines was primarily driven by higher sales of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] and GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), vaccines to prevent certain cancers and other diseases caused by HPV, in the United States reflecting the timing of public sector purchases, underlying demand and increased price, as well as higher sales of PNEUMOVAX 23 (pneumococcal vaccine polyvalent) largely driven by demand in the United States. Growth in vaccines also reflects incremental sales of approximately $65 million, of which approximately $50 million relates to GARDASIL and GARDASIL 9, due to Merck now recording vaccine sales in the 19 European countries previously part of the Sanofi Pasteur MSD vaccines joint venture, which was terminated on Dec. 31, 2016.

Pharmaceutical sales reflect a decrease in the diabetes franchise of JANUVIA (sitagliptin) and JANUMET (sitagliptin and metformin HCl), medicines that help lower blood sugar in adults with type 2 diabetes, primarily due to the timing of customer purchases in the United States as anticipated for the quarter.

Sales growth also was offset by the loss of U.S. market exclusivity in 2016 for ZETIA (ezetimibe), a medicine for lowering LDL cholesterol; CUBICIN (daptomycin for injection), an I.V. antibiotic; and NASONEX (mometasone furoate monohydrate), an inhaled nasal corticosteroid for the treatment of nasal allergy symptoms; as well as by the ongoing impact of biosimilar competition in the company’s marketing territories in Europe for REMICADE (infliximab), a treatment for inflammatory diseases. In the aggregate, sales of these products declined $686 million during the first quarter of 2017 compared to the first quarter of 2016.

Animal Health Revenue

Animal Health sales totaled $939 million for the first quarter of 2017, an increase of 13 percent compared with the first quarter of 2016, including a 1 percent negative impact from foreign exchange. Growth was primarily due to sales increases in companion animal products, driven by the BRAVECTO (fluralaner) line of products that kill fleas and ticks in dogs and cats for up to 12 weeks, as well as in ruminants, poultry and swine products. In March, Animal Health completed the acquisition of Vallée S.A., a leading privately held producer of animal health products in Brazil.

First-Quarter Expense, EPS and Related Information

The table below presents selected expense information.

 
$ in millions
            Acquisition- and                  
Divestiture- Restructuring Certain Other
First-Quarter 2017 GAAP

Related Costs 3

Costs Items

Non-GAAP 1

Materials and production $3,015 $855 $63 $-- $2,097
Marketing and administrative 2,411 20 1 -- 2,390
Research and development 1,796 11 -- -- 1,785
Restructuring costs 151 -- 151 -- --
Other (income) expense, net 58 (3) -- (9) 70
 
First-Quarter 2016
Materials and production $3,572 $1,386 $47 $-- $2,139
Marketing and administrative 2,318 2 3 -- 2,313
Research and development 1,659 35 55 -- 1,569
Restructuring costs 91 -- 91 -- --
Other (income) expense, net       48       --       --       --       48

GAAP Expense, EPS and Related Information

On a GAAP basis, the gross margin was 68.0 percent for the first quarter of 2017 compared to 61.6 percent for the first quarter of 2016. The increase in gross margin for the first quarter of 2017 was primarily driven by a lower net impact from acquisition- and divestiture-related costs and restructuring costs which reduced gross margin by 9.8 percentage points in the first quarter of 2017 as compared with 15.4 percentage points in the first quarter of 2016. The increase in gross margin also reflects the favorable effects of foreign exchange and lower inventory write-offs.

Marketing and administrative expenses were $2.4 billion in the first quarter of 2017, a 4 percent increase compared to the first quarter of 2016. The increase primarily reflects higher health care reform fee expenses, administrative costs, and promotion and direct selling expenses.

Research and development (R&D) expenses were $1.8 billion in the first quarter of 2017, an 8 percent increase compared to the first quarter of 2016. The increase reflects higher clinical development spending, partially offset by lower restructuring costs.

GAAP EPS was $0.56 for the first quarter of 2017 compared with $0.40 for the first quarter of 2016.

Non-GAAP Expense, EPS and Related Information

The non-GAAP gross margin was 77.8 percent for the first quarter of 2017 compared to 77.0 percent for the first quarter of 2016. The increase in non-GAAP gross margin was largely driven by the favorable effects of foreign exchange and lower inventory write-offs.

Non-GAAP marketing and administrative expenses were $2.4 billion in the first quarter of 2017, an increase of 3 percent compared to the first quarter of 2016. The increase was driven primarily by higher health care reform fee expenses, administrative costs, and promotion and direct selling expenses.

Non-GAAP R&D expenses were $1.8 billion in the first quarter of 2017, a 14 percent increase compared to the first quarter of 2016. The increase primarily reflects higher clinical development spending.

Non-GAAP EPS was $0.88 for the first quarter of 2017 compared with $0.89 for the first quarter of 2016.

A reconciliation of GAAP to non-GAAP net income and EPS is provided in the table that follows.

         
$ in millions, except EPS amounts       First Quarter
2017       2016
EPS
GAAP EPS $0.56 $0.40

Difference4

0.32 0.49
Non-GAAP EPS that excludes items listed below1 $0.88 $0.89
 
Net Income
GAAP net income2 $1,551 $1,125
Difference 886 1,367
Non-GAAP net income that excludes items listed below1,2 $2,437 $2,492
 
Decrease (Increase) in Net Income Due to Excluded Items:
Acquisition- and divestiture-related costs3 $883 $1,423
Restructuring costs 215 196
Other (9) --
Net decrease (increase) in income before taxes 1,089 1,619
Estimated income tax (benefit) expense (203) (252)
Decrease (increase) in net income       $886       $1,367
 

Financial Outlook

Merck has narrowed and raised its full-year 2017 GAAP EPS range to be between $2.51 and $2.63. Merck has narrowed and raised its full-year 2017 non-GAAP EPS range to be between $3.76 and $3.88, including an approximately 1.5 percent negative impact from foreign exchange at mid-April 2017 exchange rates. The non-GAAP range excludes acquisition- and divestiture-related costs, costs related to restructuring programs and certain other items.

Merck has narrowed and raised its full-year 2017 revenue range to be between $39.1 billion and $40.3 billion, including an approximately 1.5 percent negative impact from foreign exchange at mid-April 2017 exchange rates.

The following table summarizes the company’s 2017 financial guidance.

                   
      GAAP         Non-GAAP 1
 
Revenue $39.1 to $40.3 billion $39.1 to $40.3 billion**
Operating expenses Lower than 2016 Higher than 2016 by a low-single digit rate
Effective tax rate 22.0% to 23.0% 21.0% to 22.0%
EPS       $2.51 to $2.63         $3.76 to $3.88

**The company does not have any non-GAAP adjustments to revenue.

 

A reconciliation of anticipated 2017 GAAP EPS to non-GAAP EPS and the items excluded from non-GAAP EPS are provided in the table below.

         

$ in millions, except EPS amounts

      Full-Year 2017
 
GAAP EPS $2.51 to $2.63
Difference4 1.25
Non-GAAP EPS that excludes items listed below1 $3.76 to $3.88
 
Acquisition- and divestiture-related costs $3,600
Restructuring costs 600
Net decrease (increase) in income before taxes 4,200
Estimated income tax (benefit) expense (750)
Decrease (increase) in net income       $3,450
 

The expected full-year 2017 GAAP effective tax rate of 22.0 to 23.0 percent reflects an unfavorable impact of approximately 1 percentage point from the above items.

Total Employees

As of March 31, 2017, Merck had approximately 69,000 employees worldwide.

Earnings Conference Call

Investors, journalists and the general public may access a live audio webcast of the call today at 8:00 a.m. EDT on Merck’s website at http://investors.merck.com/events-and-presentations/default.aspx. Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782 and using ID code number 91134398. Members of the media are invited to monitor the call by dialing (706) 758-9928 or (800) 399-7917 and using ID code number 91134398. Journalists who wish to ask questions are requested to contact a member of Merck’s Media Relations team at the conclusion of the call.

About Merck

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com and connect with us on Twitter, Facebook, YouTube and LinkedIn. You can also follow our Twitter conversation at $MRK.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2016 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

###

1 Merck is providing certain 2017 and 2016 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management’s annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. For a description of the items, see Table 2a attached to this release.

2 Net income attributable to Merck & Co., Inc.

3 Includes expenses for the amortization of intangible assets and purchase accounting adjustments to inventories recognized as a result of acquisitions, intangible asset impairment charges and expense or income related to changes in the estimated fair value measurement of contingent consideration. Also includes integration, transaction and certain other costs related to business acquisitions and divestitures.

4 Represents the difference between calculated GAAP EPS and calculated non-GAAP EPS, which may be different than the amount calculated by dividing the impact of the excluded items by the weighted-average shares for the period.

                 
MERCK & CO., INC.
CONSOLIDATED STATEMENT OF INCOME - GAAP
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 1
           
GAAP

 

1Q17 1Q16

% Change

           
           
Sales $ 9,434 $ 9,312 1%
 
Costs, Expenses and Other
Materials and production (1) 3,015 3,572 -16%
Marketing and administrative (1) 2,411 2,318 4%
Research and development (1) 1,796 1,659 8%
Restructuring costs (2) 151 91 66%
Other (income) expense, net (1) 58 48 21%
Income Before Taxes 2,003 1,624 23%
Taxes on Income 447 494
Net Income 1,556 1,130 38%
Less: Net Income Attributable to Noncontrolling Interests 5 5
Net Income Attributable to Merck & Co., Inc. $ 1,551 $ 1,125 38%
Earnings per Common Share Assuming Dilution $ 0.56       $ 0.40 40%
         
Average Shares Outstanding Assuming Dilution 2,766 2,795
Tax Rate   22.3%         30.4%

 

(1) Amounts include the impact of acquisition and divestiture-related costs, restructuring costs and certain other items. See accompanying tables for details.

(2) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs.                                                            

 
MERCK & CO., INC.
GAAP TO NON-GAAP RECONCILIATION
FIRST QUARTER 2017
(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)
(UNAUDITED)
Table 2a
                                               

GAAP

Acquisition and Divestiture- Related Costs (1)

Restructuring Costs (2)

Certain Other Items

Adjustment Subtotal

Non-GAAP

   
Materials and production $ 3,015 855 63 918 $ 2,097
Marketing and administrative 2,411 20 1 21 2,390
Research and development 1,796 11 11 1,785
Restructuring costs 151 151 151 -
Other (income) expense, net 58 (3 ) (9 ) (12 ) 70
Income Before Taxes 2,003 (883 ) (215 ) 9 (1,089 ) 3,092
Income Tax Provision (Benefit) 447 (158

(3)

(48

(3)

3

 (3)

(203 ) 650
Net Income 1,556 (725 ) (167 ) 6 (886 ) 2,442
Net Income Attributable to Merck & Co., Inc. 1,551 (725 ) (167 ) 6 (886 ) 2,437
Earnings per Common Share Assuming Dilution $ 0.56   (0.26 ) (0.06 ) - (0.32 ) $ 0.88  
   
Tax Rate   22.3 %   21.0 %
 

Only the line items that are affected by non-GAAP adjustments are shown.

Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. Senior management’s annual compensation is derived in part using non-GAAP income and non-GAAP EPS. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP.

(1) Amounts included in materials and production costs primarily reflect $773 million of expenses for the amortization of intangible assets recognized as a result of acquisitions, as well as intangible asset impairment charges of $76 million.  Amounts included in marketing and administrative expenses reflect integration, transaction and certain other costs related to business acquisitions, including severance costs which are not part of the company's formal restructuring programs, as well as transaction and certain other costs related to business divestitures.  Amounts included in research and development expenses primarily reflect changes in the estimated fair value measurement of liabilities for contingent consideration.

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs.

(3) Represents the estimated tax impact on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments.

                                                   
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
Table 3
 
     
2017 2016 % Change
1Q 1Q 2Q 3Q 4Q

Full Year

1Q
 
TOTAL SALES (1) $9,434 $9,312   $9,844   $10,536   $10,115   $39,807 1
PHARMACEUTICAL 8,185 8,104 8,700 9,443 8,904 35,151 1
Primary Care and Women's Health
Cardiovascular
Zetia 334 612 702 671 575 2,560 -46
Vytorin 241 277 293 273 299 1,141 -13
Liptruzet 49 23 33 39 50 146 114
Adempas 84 33 40 48 49 169 158
Diabetes
Januvia 839 906 1,064 1,006 932 3,908 -7
Janumet 496 506 569 548 577 2,201 -2
General Medicine & Women's Health
Implanon / Nexplanon 170 134 164 148 160 606 27
NuvaRing 160 175 200 195 207 777 -9
Follistim AQ 81 94 73 101 87 355 -14
Hospital and Specialty
Hepatitis
Zepatier 378 50 112 164 229 555 *
HIV
Isentress 305 340 338 372 337 1,387 -10
Hospital Acute Care
Bridion 148 90 113 139 139 482 63
Noxafil 141 145 143 147 161 595 -3
Invanz 136 114 143 152 152 561 20
Cancidas 121 133 131 142 152 558 -9
Cubicin 96 292 357 320 119 1,087 -67
Primaxin 62 73 81 77 66 297 -15
Immunology
Remicade 229 349 339 311 269 1,268 -34
Simponi 184 188 199 193 186 766 -2
Oncology
Keytruda 584 249 314 356 483 1,402 134
Emend 133 126 143 137 144 549 6
Temodar 66 66 73 78 67 283 0
Diversified Brands
Respiratory
Singulair 186 237 229 239 210 915 -22
Nasonex 139 229 101 94 112 537 -40
Dulera 82 113 121 97 105 436 -27
Other
Cozaar / Hyzaar 112 126 132 131 121 511 -11
Arcoxia 103 111 117 114 108 450 -7
Fosamax 61 75 73 68 68 284 -19
Vaccines (2)
Gardasil / Gardasil 9 532 378 393 860 542 2,173 41
ProQuad / M-M-R II / Varivax 355 357 383 496 405 1,640 0
RotaTeq 224 188 130 171 162 652 19
Pneumovax 23 163 107 120 175 238 641 52
Zostavax 154 125 149 190 221 685 23
Other Pharmaceutical (3) 1,037 1,083 1,128 1,191 1,172 4,574 -4
 
ANIMAL HEALTH 939 829 900 865 884 3,478 13
 
Other Revenues (4) 310 379   244   228   327   1,178   -18
 

* 200% or greater

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

(1) Only select products are shown.

(2) Vaccine sales in 2017 include sales in the European markets that were previously part of the Sanofi Pasteur MSD (SPMSD) joint venture that was terminated on December 31, 2016. Amounts for 2016 include supply sales to SPMSD.

(3) Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were $88 million in the first quarter of 2017 and $103 million, $91 million, $135 million and $126 million for the first, second, third and fourth quarters of 2016, respectively.

(4) Other Revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities.

Distribution channels: Companies